Details of issuance or disposal
Monthly conversion and exercise status of Series 3 unsecured convertible bonds with stock acquisition rights issued through a private placement, with provisions for adjustment of the conversion price, and Series 8 stock acquisition rights, with provisions for adjustment of the exercise price
Series 3 convertible bonds with stock acquisition rights: 590,731 new shares; Series 8 stock acquisition rights: 0 shares
The lower thin line represents the existing number of shares to which these shares will be added.
1.5% conversion/exercise ratio subject to the conversion and exercise limits (590,731 shares / 40,554,949 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly conversion and exercise status of Series 3 unsecured convertible bonds with stock acquisition rights issued through a private placement, with provisions for adjustment of the conversion price, and Series 8 stock acquisition rights, with provisions for adjustment of the exercise price |
| Number of shares to be issued or disposed of | Series 3 convertible bonds with stock acquisition rights: 590,731 new shares; Series 8 stock acquisition rights: 0 shares |
| Intended allottee | EVO FUND (issued on 1 June 2026) |
| Dilution Rate | 1.5% conversion/exercise ratio subject to the conversion and exercise limits (590,731 shares / 40,554,949 shares) |
| Total number of issued shares | 41,292,986 shares (as of the end of the month preceding the subject month) → Not disclosed |
| Exercise price | Conversion price for the Series 3 convertible bonds with stock acquisition rights: ¥74.7–¥78.3 during the subject month. Exercise price for the Series 8 stock acquisition rights: ¥82.0–¥88.0 during the subject month. Floor under the adjustment provisions: Not disclosed |
| Number of Stock Acquisition Rights | Series 8 stock acquisition rights: 100,000 issued in total; 99,000 unexercised as of the end of the subject month (9,900,000 shares). Series 3 convertible bonds with stock acquisition rights: Not disclosed |
| Procedures under the Corporate Code of Conduct | Report on compliance with the conversion and exercise limits under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 1 June 2026 / Type New shares issued through a private placement (in-kind contribution (debt-to-equity swap)), Series 3 unsecured convertible bonds with stock acquisition rights, and Series 8 stock acquisition rights / Amount Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly conversion and exercise status. No use of funds or reasons for the conversions and exercises are stated.